


2000 6



2000


6

1.		1
1.		1
2.		5
3.	가	5
2.		6
1.		6
2.		7
3.		8
가.		8
·		9
·		11
·		11
4.		11
5.		12
6.		13
·		14
1.		14

가.		14
.		16
2.		18
3.		20
가.		20
.	1	22
4.	8	
		24
5.		25
가.	Daonil	25
.	Glucophage	26
.		27
1.		27
2.		33
3.		36
.		37
		38
		44

1. Borgs Scale		10
2.		15
3.		16
4.		17
5.		19
6.	8	
		21
7.	8	
	1	23
8.		24
9.	8	
	Daonil	25
10.	8	
	Glucophage	26

1.		6
2.		13
3.		20
4.	1	22



Mann-Whitney test

1.

($p < 0.05$).

2. 1

($p < 0.05$).

3.

8

($p < 0.05$),

94%

4. Daonil

($p < 0.05$).

5. Glucophage

($p < 0.05$).

가 , 가

.

•

1.

가 (, 1995),

5% ,

가 (, 1993).

(, 1985), ,

.

, (1) , (

2) , , (

, 1995)

, 5- 10%

(, 1985).

,

(Wallenberg , 1981).

가

(Leon, 1989),

200mg/dl
270
mg/dl
(, 1999).

(, 1984)
가 (Taylor, 1993).
가
가
가
(Amir, 1990)

1919 Allen, Lawrence
(,
1995; , 2000).

80%,
15%, 5% (, 1998),
(, 1997).

가 가

(, 1998)

가

,

가

가

가

가

(Horton, 1991).

가 ,

가

,

가

(, 1998),

(, 1995).

(, 1990; , 1992; , 1993; , 1995),

25

8

2.

1 50 , 5 , 8

.

,

,

3. 가

가 1.

가 2.

.

•

1.

(Time Series) . . . ,

8

8

(Quasi-Experimented Study) (1).

O	X	O	O - O =de
O		O	O - O =dn

O : ()

de :

X : 1 50 5 8

O : 8 ()

dn :

1.

2.

가

, 1 ,
, ,

가

2 100- 300mg/dℓ ,

가

,

12

90%

가

12

1

6 1999 5 9

5

6

1999 10 2000 2

2

3.

가.

, , ,
 , , (cm)
 (CAS ,)
 (kg) , Broca
 [(- 100) × 0.9] [(/
) × 100] .

3

(: :) 60:20:20

(Solco ,)

, 24

S

1 8 1 50 5
 1 5 가
 35 5
 2 2
 1 5

Borg(1982)

Borgs Scale(1)

1. Borgs Scale

6	
7	가
8	
9	가
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	

.
(mg/dl) 1 (mg/dl)
One Touch Basic (Lifescan ,) .

4.

5.

SAS(Statistical Analysis

System)


.

,

Mann-Whitney test

.

6.



2.

•

1.

가.

6 가 6 ,
1 , 5 , 4 , 가 2
, 1 , 2 , 1 , 가 2 ,
4 , 1 , 1 . 6
가 6 , 1 5 ,
가 1 , 1 , 가 4 , 1 , 2
, 2 , 가 1 , 4 , 2
(2). .

2.

(n=6)		(n=6)	
n		n	
6		6	
1		1	
5		5	
0		1	
4		1	
2		4	
0		1	
0		2	
1		2	
2		0	
1		0	
2		1	
4		4	
1		2	
1			
6		6	

20-37 25 ,
 24 . 174.3cm,
 176.0cm , 62.7kg, 71.8kg
 , 93.7%, 104.5%
 , 35.0 , 45.3
 , 2116.7kcal, 1993.3
 kcal (3).

3.

	(n=6)			(n=6)		
	Mean ± S.D	Min	Max	Mean ± S.D	Min	Max
()	25.0 ± 6.10	20	37	24.0 ± 6.51	20	37
(cm)	174.3 ± 5.09	168	181	176.3 ± 2.73	173	180
(kg)	62.7 ± 9.99	55	82	71.8 ± 13.35	50	85
(%)	93.7 ± 12.86	79	112	104.5 ± 18.63	74	119
()	35.0 ± 49.32	2	130	45.33 ± 43.93	2	130
(Kcal)	2116.7 ± 318.85	1800	2500	1933.3 ± 256.83	1700	2400

가 , , , , (4).

4.

Mean rank		z	p
(n=6)	(n=6)		
7.3	5.7	0.73	0.466
5.7	7.3	-0.73	0.468
5.2	7.8	-1.20	0.230
5.2	7.8	-1.20	0.230
5.9	7.1	-0.49	0.626
7.8	5.3	1.16	0.244

† Mann-Whitney test

2.

214.50mg/dl, 179.67mg/dl, 1
271.50mg/dl,
260,33mg/dl . Daonil
10.00mg, 10.83mg ,
Glucophage 1000.00mg,
833.33mg .

가 (5).

5.

	Mean		z	p
	(n=6)	(n=6)		
(mg/dl)				
	214.50	179.67	1.04	0.298
	271.50	260.33	1.36	0.173
(mg)				
Daonil	10.00	10.83	1.47	0.142
Glucophage	1000.00	833.33	0.87	0.383

† Mann-Whitney test

* $p < 0.05$

3.


가.

112.33mg/dℓ (p < 0.05).

214.50mg/dℓ (p < 0.05).

179.67mg/dℓ (p > 0.05)

140.67mg/dℓ (p > 0.05) (3).



(p < 0.05)(6).

6. 8

Mean \pm SD		z	p
(n=6)	(n=6)		
112.33 \pm 10.67	140.00 \pm 17.06	-2.48	0.013*

† Mann-Whitney test

* p < 0.05

1

1

144.50mg/dℓ


271.50mg/dℓ

(p < 0.05).

260.33mg/dℓ

216.50mg/dℓ

(p > 0.05)(4).



1
 (p < 0.05) (n = 7).

7.	8		1		
		Mean ± SD			
		(n=6)	(n=6)	z	p
1	144.50 ± 24.93	216.50 ± 34.51	-2.65	0.008*	

† Mann-Whitney test

*p < 0.05

4. 8

8

· , , (p < 0.05),

86% , 가

94% . 8

8% (8).

8. 8

	(n=12)			(n=12)		
	(SE)	t-	p	(SE)	t-	p
	3.60(2.341)	1.54	0.168	-0.42(2.316)	-0.18	0.861
	0.03(0.538)	0.05	0.960	0.02(0.398)	0.04	0.971
	-0.38(0.289)	-1.30	0.235	-0.01(0.257)	-0.01	0.987
	1.13(0.254)	4.46	0.003*	0.78(0.231)	3.37	0.015*
(1, 0)				35.93(13.743)	2.62	0.040*
R ²	0.86			0.94		
(Adj R ²)	(0.79)			(0.88)		
F	11.07			17.60		
()	(0.0038)			(0.0016)		

* p < 0.05

5.

가.

Daonil

Daonil

8

6

,

4

가

, 2

가

, Mann-Whitney test

(p 0.05)(9).

9.

8

Daonil

	(n=6)			(n=6)			z	p
	가			가				
Daonil	0	6	0	4	0	2	-2.43	0.015*

† Mann-Whitney test

* p < 0.05

. **Glucophage**
 Glucophage 8 2
 , 4 가 , 5
 가 ,1 가 , Mann-Whiney test
 (p 0.05)(10).

10.	8						Glucophage	
	(n=6)			(n=6)			z	p
	가			가				
Glucophage	0	2	4	5	0	1	-2.19	0.029*

† Mann-Whitney test

* p < 0.05

•

1.

1 20-60
, 60-90% , 3-5
(American College of Sports Medicine,
1990).

가 가 (Horton, 1988;
Lampman, 1991), ,

가 (, 1995).

가
, , , (Bell,
1992; Williams, 1994; Wallberg-Herriksson, 1998),
140mmHg , , 300mg/
dℓ , , ,
, 가
(, 1996)

, , , , .

, , .

25 ,

, , (Blake, 1992).

가 , , ,

가

가 (, 1988),

가

5-10 (, 1997).

가

(Bell, 1992),

, , ,

(Borkman, 1993; Ivy, 1997).

, 가

(Bell, 1992; , 1999).

1 , 30 , 30 , 30

300

(, 1995), 40-60

(Robertson, 1984).

5-10 가

1/3

가

2/3

(Robertson, 1984)

5

가

가

,

,

,

,

35

5

,

2 ,

2

1

5

Borg(1982)

,

1

가

50-70%

(

, 1996),

40-60
 30-60 가 가 가
 (, 1998). 1 50
 2
 가 ,
 3 (Young, 1995),
 5 (Bell, 1992). 5
 (1996) 36% ,
 가 가
 , (1998) 67.3%가 ,
 1
 (, 1998).
 가 가 가
 , 가
 가 .

가 . 가

(Eriksson, 1997).

, ,
.

(, 1998). 200mg/dl

. Daonil

, 3 7

Glucophage - Glucosidase

가 .

가 (, 1998).

가 ,

,

,

.

, 25

1 50 ,

, 5 , 8

.

2.

1 가
,
($p < 0.05$). 8
($p < 0.05$),
94% . Vranic(1979)
10
Schneider (1984) 가 Reitman
(1984) 6- 10
Rogers(1989)
Ruderman(1990) 6
(1986) 2
, (1990)
14 4 , (1993) 30
6 12 ,
(1992) 25 6 가
(1995) 12 14
가 .

Hedden(1989) 3
1 20 1 3 6
가 , 6 10
가 Skarftors(1987) 48
2 40
8 60
가
Segal (1991) ,
, insulin sensitivity
. 8 1
가 ,
Daonil Glucophage
(p < 0.05). Barnard(1994)
3
71%가 Heath (1987) Zuni
86 30
56 2 ,
, , 가
30% 20% ,
29% 27% , 가 .

Gudet (1998)

9

가 , 60
가 ,

가 .

가

3.

, 가 12 .

•

1999 5 1 2000 2 28

12

1 50 , 5 , 8

1.

(p < 0.05).

2. 1

(p < 0.05).

3. 8

(p < 0.05),

94% .

4. Daonil

(p < 0.05).

5. Glucophage

(p < 0.05).

가

,

가

.

. 4
 1998; 29-45
 , , 99. ,
 1999; 84-91

 Apolipoprotein
 , 1995

 , 1992
 2 , 1995
 1999; 23(1): 39-42
 - -. 1997; 85-109
 , 1996; 51-66
 , 1998; 69-75
 4
 1998; 15-28
 , ,
 , . 가 1996; 17: 223-231

. Health & Sports Medicine 2000; 3: 79-86

, 1993

. 4 1999; 27-43

. 2

. , 1990

. , 1988

. , 1995

. 1985; 9(1): 5-9

. 1986; 29(3): 313-321

.

1984; 22(7): 14 41

. 가

. , 1993

.

. , 1998

. 9 1995; 51-55

- American College of Sports Medicine. The recommended quantity and quality of exercise of developing and maintaining cardiorespiratory and muscular fitness in healthy adults. *Med Sci Sports Exerc* 1990; 22: 265-274
- Amir S, Ralin C, Galatzer A. Cognitive and behavioral determinants of compliance in diabetes. *Health and Social Work* 1990; 15(2): 144-151
- Barnard RJ, Jung T, Inkeles SB. Diet and exercise in the treatment of NIDDM. *Diabetes Care* 1994; 17: 1469-1472
- Bell DS. Exercise for patients with diabetes. *Postgraduate Medicine* 1992 ; 92(1): 193-198
- Blake GH. Control of type II diabetes. *Postgraduate Medicine* 1992; 82(6): 129-137
- Bogardus C, Ravussin E, Robbins DB, et al. Effects of physical training and diet therapy on carbohydrate metabolism in patients with glucose intolerance and non-insulin-dependent diabetes mellitus. *Diabetes* 1984; 33: 311-318
- Borg G. Psycho-physical bases of perceived exercise. *Med Sci Sports Exerc* 1982; 14: 377-381
- Borkman M, Campbell LV. Non-insulin-dependent diabetes mellitus. *Australian Family Physician* 1993; 22(9): 1549-1560
- Eriksson J, Taimela S, Korvisto VA. Exercise and the metabolic syndrome. *Diabetologia* 1997; 40: 125-135

- Gudat U, Bingert S, Kemmer F, Heinmann L. The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus. *Diabetic Medicine* 1998; 15: 194-198
- Heath GW, Leonard BE, Wilson BE, et al. Community based exercise intervention: Zuni: diabetes project. *Diabetes Care* 1987; 10: 579-583
- Hedden C. Exercise and NIDDM. *The Diabetes Educ* 1989; 14: 178-180
- Horton ES. Exercise and diabetes mellitus. *Med Clin North Am* 1988; 72: 1301-1317
- Horton ES. Exercise in the treatment of NIDDM(Applications for GDM?). *Diabetes* 1991; 40(2): 175-178
- Ivy JL. Role of exercise training in the prevention and treatment of insulin resistance and non-insulin- dependent diabetes mellitus. *Sports Med* 1997; 24: 321-336
- King H, Kriska AM. Prevention of type II diabetes by physical training. *Diabetes Care* 1992; 15(4): 1794-1799
- Lampman RM, Scheingart DE. Effects of exercise training on glucose control, lipid metabolism, and insulin sensitivity in hypertriglyceridemia and non-insulin-dependent diabetes mellitus. *Med Sci Sports Exerc* 1991; 23: 703-712
- Leon AS. Patients with diabetes mellitus. Exercise in modern medicine. Baltimore, Williams and Wilkins 1989; 118-145

- Reitman JS, Vasquez B. Improvement of glucose homeostasis after exercise training in non-insulin-dependent diabetes. *Diabetes Care* 1984; 7: 434
- Robertson C. Clear the exercise hurdles for your diabetic patient. *Nursing*. 1984; 84: 58-69
- Rogers MA. Acute effects of exercise on glucose tolerance in non-insulin-dependent diabetes. *Med Sci Sports Exerc* 1989; 21: 362-368
- Ruderman N, Apeiiom AZ, Schneider SH. Exercise in therapy and prevention of type II diabetes. *Diabetes Care* 1990; 13(11): 1163-1168
- Schneider SH, Anorosa LF, Khachadurian AK, et al. Studies on the medianism of improved glucose control during regular exercise in non-insulin-dependent diabetes. *Diabetologia* 1984; 26: 355-360
- Segal KR, Edano A, Abalos A, et al. Effect of exercise training on insulin sensitivity and glucose metabolism in lean, obese, and diabetic men. *J Appl Physiol* 1991; 71: 2402-2411
- Skarfors ET. Physical training as for type diabetes in elderly men, a feasibility study over 2 years. *Diabetologia* 1987; 30: 930-933
- Taylor R. Management of non-insulin-dependent diabetes. *Eye* 1993; 7: 298-301
- Vranic M, Berger M. Exercise and diabetes mellitus. *Diabetes* 1979; 28: 107
- Wallberg-Herriksson H, Rincon J, Zierath HR. Exercise in the management of non-insulin- dependent diabetes mellitus. *Sports Med* 1998; 25(1): 25-35

Wallenberg M, Munnarsson R. Physical training in diabetes: discussion between changes in insulin sensitivity and blood glucose regulation. Clin Res 1981; 29: 426

Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet 1994; 343: 95-100

Young JC. Exercise prescription for individuals with metabolic disorders. Sports Med 1995; 19(1): 43-54

Zinman B, Vranic M. Diabetes and exercise. Med Clin North Am 1985; 69: 145

ABSTRACT

The Effects of Exercise Program on Blood Glucose and Medication in Non-Insulin-Dependent Diabetics.

Ae-Young Lee

Graduate School of

Health Science and Management

Yonsei University, Seoul, Korea

(Directed by Professor Sae-il Chun, M.D.)

The purpose of this study was to investigate the effects of 8 week's exercise program on blood glucose and medication in non-insulin-dependent diabetics.

The subjects of this study were selected 12 patients who had been hospitalized to Armed Forces Capital Hospital. They were composed of a regular exercise group of 6 subjects and an irregular exercise group of 6 subjects. Both groups were tested twice; 1st test prior to exercise and 2nd test after 8 weeks of exercise.

Test items for measurement of effects were F. B. S. and postprandial glucose level as indicator of blood glucose and dosages of oralhypoglycemic agents as indicator of medication.

Statistical analysis was performed using Mann-Whitney test and multiple regression model.

The results obtained from this study were as follows:

1. Fasting blood sugar was significantly lowered in regular exercise group comparing to irregular exercise group($p < 0.05$).
2. Postprandial blood sugar was significantly lowered in regular exercise group comparing to irregular exercise group($p < 0.05$).
3. The effect of exercise program on glucose difference after 8 weeks exercise program was significant statistically($p < 0.05$) and the describabilities of the multiple regression model built reflected 94% .
4. Dosage of Doanil was significantly reduced in regular exercise group comparing to irregular exercise group($p < 0.05$).
5. Dosage of Glucophage was significantly reduced in regular exercise group comparing to irregular exercise group($p < 0.05$).

In conclusion, exercise program can be effective for controlling NIDDM without complication in early diagnosis. The results of this study has a general limitation due to the restricted number of cases and the gender. It is recommended that a more detailed protocols be developed for further study.